Linden Thomas Advisory Services’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.22M | Buy |
4,235
+1,045
| +33% | +$549K | 0.24% | 123 |
|
|
2025
Q1 | $2.02M | Buy |
3,190
+135
| +4% | +$85.6K | 0.26% | 126 |
|
|
2024
Q4 | $2.18M | Buy |
3,055
+241
| +9% | +$172K | 0.28% | 116 |
|
|
2024
Q3 | $2.96M | Buy |
2,814
+245
| +10% | +$258K | 0.4% | 54 |
|
|
2024
Q2 | $2.7M | Sell |
2,569
-211
| -8% | -$222K | 0.42% | 51 |
|
|
2024
Q1 | $2.68M | Buy |
2,780
+173
| +7% | +$167K | 0.43% | 41 |
|
|
2023
Q4 | $2.29M | Buy |
2,607
+136
| +6% | +$119K | 0.43% | 47 |
|
|
2023
Q3 | $2.03M | Sell |
2,471
-626
| -20% | -$515K | 0.45% | 39 |
|
|
2023
Q2 | $2.23M | Buy |
3,097
+61
| +2% | +$43.8K | 0.49% | 33 |
|
|
2023
Q1 | $2.49M | Buy |
3,036
+106
| +4% | +$87.1K | 0.62% | 25 |
|
|
2022
Q4 | $2.11M | Buy |
+2,930
| New | +$2.11M | 0.6% | 25 |
|